es-sclc news - Search News

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab govitecan-hziy), has been granted a second Breakthrough Therapy designation by the FDA for a lung cancer indication.

Hosted on MSN · 2d

Gilead gets FDA breakthrough therapy status for Trodelvy

Gilead Sciences (NASDAQ:GILD) said it has received FDA Breakthrough Therapy Designation for its antibody-drug conjugate Trodelvy in the treatment of extensive-stage small cell lung cancer, or ES-SCLC.

Daily · 1d

Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for

Business Insider · 3d

FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer

(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

The Pharma Letter2d

FDA Breakthrough status for Trodelvy in ES-SCLC

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...

Targeted Oncology2d

FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...

pharmaphorum5d

NICE recommends Roche's Tecentriq in ES-SCLC following price rethink

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC) in second draft ...

GlobalData on MSN3d

GSK’s lung cancer therapy gains EMA PRIME designation

GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics